
Wayne Russell Godfrey MD
Hematologic Oncology
Chief Medical Officer/ImmTak Consulting
Join to view full profile
4927 NE Tolo RoadBainbridge Island, WA 98110
Phone+1 650-521-2770
Dr. Godfrey is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Wayne Godfrey is an oncologist specializing in hematologic oncology, practicing on Bainbridge Island, WA. He completed his education and fellowship at Stanford University and his medical degree at Washington University in St. Louis School of Medicine. Dr. Godfrey has held leadership roles, including Chief Medical Officer at ImmTak Consulting and Janux Therapeutics, and has experience in hematologic oncology and immuno-oncology. He has contributed significantly to research, publishing works in notable journals like Blood and The New England Journal of Medicine, with one of his publications garnering 861 citations.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 1997 - 1999
Stanford Health Care-Sponsored Stanford UniversityFellowship, Rheumatology, 1991 - 1996
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1989 - 1990
University of Wisconsin Hospitals and ClinicsInternship, Internal Medicine, 1988 - 1989
WashU MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2009 - 2027
WA State Medical License 2005 - 2027
Publications & Presentations
PubMed
- 17 citationsCombinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.Sven de Vos, Nina D. Wagner-Johnston, Steven Coutre, Ian W. Flinn, Marshall T. Schreeder
Blood Advances. 2016-12-13 - 211 citationsA phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven Coutre
Blood. 2014-05-29 - 180 citationsIdelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Ian W. Flinn, Brad S. Kahl, John P. Leonard, Richard R. Furman, Jennifer R. Brown
Blood. 2014-05-29
Press Mentions
Marginal Zone LymphomaAugust 22nd, 2017
Marginal Zone LymphomaAugust 18th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: